Company / R&D Expense
Twist Bioscience Corp R&D Expense History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$80.3M
FY2025
5-year range
$69.1M / $120.3M
FY2021-FY2025
Trend
-11.6%
vs FY2024
Sector context
#156 of 209
Health Care
What the data says
Twist Bioscience Corp's r&d expense of $80M is lower than 75% of companies in the Health Care sector (FY2025). R&D Expense has declined for 3 consecutive years, from $120M in FY2022 to $80M in FY2025.
Based on SEC 10-K filings.
$80M in FY2025 with a 5-year CAGR of +13.3%.
Declined from $107M to $80M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -12.6%
- 5-Year CAGR
- +13.3%
- 10-Year CAGR
- -
Sector benchmark
Bottom 25% in Health CareTop 75% of 209This company $80.3M Sector average $647.6M
▼
-87.6% below sector average
Key checks
Key Insights
- Twist Bioscience Corp's r&d expense has declined for 3 consecutive years.
- 5-year CAGR of +13.3%, indicating consistent growth.
- In FY2025, r&d expense decreased 11.6% year-over-year.
- Ranks #156 out of 209 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.79 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $80.3M | -11.6% |
| FY2024 | $90.9M | -15.0% |
| FY2023 | $106.9M | -11.1% |
| FY2022 | $120.3M | +74.2% |
| FY2021 | $69.1M | +60.6% |
| FY2020 | $43.0M | +20.5% |
| FY2019 | $35.7M | +75.4% |
| FY2018 | $20.3M | +6.1% |
| FY2017 | $19.2M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026